MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology (MAIA) completed Part C enrollment in its Phase 2 THIO-101 trial of ateganosine for non-small cell lung cancer. Across its ongoing Phase 2 and pivotal Phase 3 trials, 150 patients have received ateganosine followed by an immune checkpoint inhibitor, a cancer immunotherapy. THIO-101 evaluates ateganosine followed by cemiplimab and reported 90.5% interim disease control among efficacy-evaluable patients with at least one tumor scan after treatment began.
The Phase 3 THIO-104 trial has enrolled 65 patients, reaching 65% of its target to enroll and dose 100 patients by year-end 2026. It studies third-line patients whose disease progressed after chemotherapy and checkpoint inhibitor treatment. MAIA remains on track for a targeted 2027 interim analysis. Ateganosine received FDA Fast Track designation for this cancer in July 2025; if approved, it will receive five-year New Chemical Entity marketing exclusivity.
MAIA Biotechnology (MAIA) received regulatory approval to expand its pivotal Phase 3 THIO-104 non-small cell lung cancer trial into Spain and Portugal.
The company can now begin screening patients in both countries following clearances from Spain’s AEMPS and Portugal’s INFARMED. Spain and Portugal are described as important NSCLC markets, with an estimated 30,000 new lung cancer cases annually across the two nations. THIO-104 targets patients with advanced NSCLC who have progressed after standard-of-care treatments, potentially improving access to investigational options where adoption of new lung cancer therapies has historically lagged. To date, 65 NSCLC patients resistant to chemotherapy and checkpoint inhibitors have been enrolled across 28 sites in six European countries and 10 sites in Taiwan. MAIA aims to have 100 patients dosed by year-end 2026 and expects to conduct an interim survival analysis in 2027.
MAIA Biotechnology (MAIA) reported progress in its pivotal Phase 3 THIO-104 trial of ateganosine as a third-line treatment for advanced non-small cell lung cancer, with enrollment reaching 65 randomized patients and 38 active sites across six countries.
The company expects additional clinical sites to begin enrolling and says it remains on track to exceed 100 randomized patients by year-end. MAIA cites prior statistical assessments indicating a "very high probability of technical success" for regulatory approval. In the ongoing Phase 2 THIO-101 trial, ateganosine sequenced with a checkpoint inhibitor achieved a 90.5% interim disease control rate in heavily pretreated third-line NSCLC, compared with reported 25%–35% DCRs for standard third-line chemotherapy regimens.
The FDA granted ateganosine Fast Track designation for NSCLC in July 2025, enabling more frequent FDA interaction, potential rolling review, and eligibility for Accelerated Approval and Priority Review, as well as five-year New Chemical Entity marketing exclusivity if approved.
MAIA Biotechnology (MAIA) has dosed the first U.S. patient in its ongoing Phase 2 THIO-101 trial of ateganosine in third-line non-small cell lung cancer (NSCLC), marking the start of the U.S. expansion of this global study.
The U.S. Phase 2 expansion is funded by a $2.3 million NIH grant to support evaluation in third-line treatment, and three sites have been activated in the United States. Ateganosine, MAIA’s telomere-targeting lead candidate, has FDA Fast Track designation and is described by the company as a dual-mechanism therapy that disrupts telomere structure and function in cancer cells while inducing immune activation.
Prior THIO-101 Parts A and B data show overall survival beyond 24 months in eight patients treated with ateganosine sequenced with a checkpoint inhibitor. The company said that patients are now enrolled across four continents and that it believes data from the THIO-101 program may support a potential pathway toward FDA accelerated approval.
MAIA Biotechnology (MAIA) reported open market purchases of its common stock by board member Ramiro Guerrero and Founder and CEO Vlad Vitoc in August and September 2026. Guerrero acquired 185,078 shares between August 20 and September 10 for approximately $252,284 at an average price of $1.36 per share, while Vitoc bought 73,000 shares on September 14 at an average price of $1.37 per share. The leaders said these investments reflect confidence in MAIA’s science, clinical strategy and long-term commercial potential.
MAIA is conducting THIO-104, an ongoing pivotal Phase 3 trial of ateganosine sequenced with checkpoint inhibitor cemiplimab versus investigator’s choice in third-line non-small cell lung cancer. The company has previously stated that statistical assessments suggest a high probability of technical success and potential early full commercial approval if interim Phase 3 data are consistent with Phase 2 THIO-101 results. In Part C of THIO-101, MAIA recently reported a disease control rate of 90.5% in the efficacy evaluable population. As of September 14, 2026, directors and officers hold 21.34% of MAIA’s shares.
MAIA Biotechnology (MAIA) presented oral and poster data on its first- and second-generation telomere-targeting cancer therapies at the XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026) in Barcelona, Spain.
The company highlighted its lead candidate ateganosine, described as a first-in-class therapy that targets cancer-cell telomeres while engaging antitumor immune responses, and introduced next-generation divalent prodrugs that combine ateganosine with a complementary DNA-targeting agent in a single molecule. These dual-pharmacophore candidates showed increased anticancer activity in preclinical in vitro and in vivo models and are being optimized based on structural features associated with the strongest antitumor effects. MAIA stated that these results expand its platform beyond ateganosine and support pipeline development across multiple tumor types.
MAIA Biotechnology (NYSE American: MAIA) reported initial efficacy data from Part C of its Phase 2 THIO-101 expansion trial in third-line advanced non-small cell lung cancer.
Ateganosine followed by cemiplimab achieved a 90.5% disease control rate (19/21 patients) in an efficacy-evaluable, heavily pre-treated population, with an acceptable safety profile and completed international enrollment.
MAIA Biotechnology (NYSE American: MAIA) completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial of ateganosine in third-line non-small cell lung cancer. Part C randomized 41 CPI- and chemotherapy-resistant patients to ateganosine plus cemiplimab or ateganosine alone.
According to MAIA, Parts A and B showed median survival of 17.8 months versus expected 5.8 months, with eight patients living beyond two years and one over 33 months. The FDA has granted Fast Track designation for ateganosine in NSCLC.
MAIA Biotechnology (NYSE American: MAIA) has opened patient enrollment at Winship Cancer Institute of Emory University, the third U.S. site in its Phase 2 THIO-101 expansion trial.
The open-label study evaluates telomere-targeting agent ateganosine followed by cemiplimab as third-line treatment for NSCLC patients resistant to checkpoint inhibitors and chemotherapy, a setting with no FDA-approved options. According to MAIA, earlier trial parts showed strong early efficacy, with some patients’ survival exceeding two years.
MAIA Biotechnology (NYSE American: MAIA) activated its second U.S. clinical site for the international Phase 2 THIO-101 expansion trial at Central Alabama Research in Homewood, Alabama. The study evaluates lead therapy ateganosine as third-line treatment for NSCLC patients who failed checkpoint inhibitors and chemotherapy.
The THIO-101 expansion now has 44 active sites in 6 countries plus 2 in the U.S., and may support an accelerated FDA approval filing. MAIA is also enrolling a pivotal Phase 3 trial assessing overall survival in up to 300 patients, under an FDA Fast Track designation.